Rectal Cancer

Rectal Carcinoma

Male, 64 years

Patient Internal ID 372282674

ICD-10 code

C20 Malignant Neoplasm of Rectum

Diagnosis (Incl. Metastases/Stage) and Year

Rectal Carcinoma pT4N0M0 G2 Stage IIB (2013). Disease progression in February 2017 – Multiple Metastases in the Lungs. In February 2020, Disease progression in the Lungs.

Previous Treatment

Surgery (Rectal resection), Chemotherapy (FOLFOX4), Surgery (Resection of Lung Metastasis), Chemotherapy (FOLFOX) + Biologic Therapy (Bevacizumab), Chemotherapy (Capecitabine) + Biologic Therapy (Bevacizumab), Chemotherapy (FOLFIRI) + Biologic Therapy (Bevacizumab), Chemotherapy (Trifluridine/ Tipiracil), Target Therapy (Regorafenib).

Prognosis and Survival Expectation

The prognosis remains poor for Advanced Rectal Cancer, with a median survival of ~28 months from diagnosis.

Treatment Provided

Autologous DCV (10 doses) and CIK (4 doses) over a period of 14 months.

Patient Survival/Condition and Year
Date of Review: 30/12/2023

The patient has survived for 10 years since the diagnosis, and 6 years and 8 months since the disease progression. It can be concluded that the addition of Immunotherapy, alongside Surgery, Chemotherapies, Biological Therapy and Target Therapy, has extended patient survival by an estimate of around 52 months.